Status:

COMPLETED

Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Preparation and Procedure

Lead Sponsor:

Medtronic - MITG

Conditions:

Bowel Diseases

Eligibility:

All Genders

18-75 years

Brief Summary

The purpose of this study is to evaluate the effect of the PCCE preparation and procedure on colon cleansing level and excretion rate.

Detailed Description

The evaluation of subjects with suspected colonic disease includes endoscopic imaging by colonoscopy and radiologic imaging such as air-contrast barium enema, or CT colonography. The PillCam® platform...

Eligibility Criteria

Inclusion

  • Subjects over ≥ 50 years of age scheduled for colorectal cancer screening
  • Subjects over ≥ 50 years of age with one or more of the following clinical symptoms: rectal bleeding, hematochezia, melena, positive FOBT, recent change of bowel habits, or diarrhea/constipation of recent onset.
  • Subject ≥ 18 years of age with one of the following:
  • Positive findings (≥ 10 mm polyps) in the colon on a GI radiographic study (BE, CT scan, etc) OR
  • Personal history of colorectal cancer (CRC) or adenomatous polyps and ≥5 years since last colonoscopy

Exclusion

  • Subject has dysphagia or any swallowing disorder
  • Subject has congestive heart failure
  • Patient has significant renal insufficiency, heart disease or any other condition that the investigator would expect to increase the risk of complications from magnesium citrate, such as dehydration or electrolyte imbalance
  • Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator
  • Subject has a cardiac pacemaker or other implanted electro medical device.
  • Subject has any allergy or other known contraindication to the medications used in the study
  • Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
  • Subject with any condition believed to have an increased risk for capsule retention such as Crohn's disease, intestinal tumors, radiation enteritis, or NSAID enteropathy,
  • Subject with gastrointestinal motility disorders
  • Subject has known delayed gastric emptying
  • Subject has any condition, which precludes compliance with study and/or device instructions.
  • Women who are either pregnant or nursing at the time of screening, or are of child-bearing potential and do not practice medically acceptable methods of contraception such as: surgical sterilization, approved hormonal contraceptives (i.e. birth control pills, Depo-Provera), barrier methods (i.e. condom or diaphragm) used with a spermicide and an intrauterine device (IUD)
  • Subject suffers from life threatening conditions
  • Subject currently participating in another clinical study

Key Trial Info

Start Date :

October 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 1 2009

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00885235

Start Date

October 1 2008

End Date

August 1 2009

Last Update

July 31 2019

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

University of Indiana Hospital

Indianapolis, Indiana, United States, 46202

2

University of North Carolina

Chapel Hill, North Carolina, United States, 27599

3

Digestive Care Inc.

Beavercreek, Ohio, United States, 45440

4

Gastroenterology Associates of Tidewater

Chesapeake, Virginia, United States, 23320